Neurocrine Biosciences started a Phase 2 clinical study of NBI-1065890, a next generation VMAT2 inhibitor for tardive dyskinesia. The trial focuses on evaluating safety, tolerability, and potential ...
Patients on antipsychotics need to be regularly monitored for signs of tardive dyskinesia, a medication-induced movement disorder diagnosed when the involuntary movements persist for at least a month ...
Akathisia and tardive dyskinesia are neurological movement disorders that can develop as side effects of certain dopamine-blocking medications, particularly antipsychotics. Because both can involve ...
Tardive dyskinesia affects hundreds of thousands of people, yet it often goes unrecognized. The symptoms can be easy to overlook at first — a subtle lip twitch, a slight hand movement, or a bit of ...
Objective: Ultra-high risk criteria were developed to identify prodromal symptoms of psychosis, although the transition does not occur in most individuals. This highlights the need to identify ...
A movement disorder like tardive dyskinesia is known to be difficult and very frustrating to live with. People of African descent, females (especially post-menopausal women), older adults over the age ...
Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous ...
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile ...
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results